Effect of different Analgesics as a Premedication on Postendodontic Pain – A Literature Review
Jerry Jose1, Nivedhitha Malli Sureshbabu2*
1 Post Graduate Student, Department of Conservative Dentistry and Endodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical
and Technical Sciences, Saveetha University, Chennai 600077, Tamil Nadu, India.
2 Head of the Department, Department of Conservative Dentistry and Endodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical
and Technical Sciences, Saveetha University, Chennai 600077, Tamil Nadu, India.
*Corresponding Author
Nivedhitha Malli Sureshbabu,
Head of the Department, Department of Conservative Dentistry and Endodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences,
Saveetha University, 162, Poonamallee High Road, Chennai 600077, Tamil Nadu, India.
Tel: +91 9840912367
E-mail: nivedhithamallisureshbabu@gmail.com
Received: May 19, 2021; Accepted: August 11, 2021; Published: August 18, 2021
Citation:Jerry Jose, Nivedhitha Malli Sureshbabu. Effect of different Analgesics as a Premedication on Postendodontic Pain – A Literature Review. Int J Dentistry Oral Sci. 2021;8(8):3968-3975. doi: dx.doi.org/10.19070/2377-8075-21000811
Copyright: Nivedhitha Malli Sureshbabu©2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
Pain is seen to be a subjective experience and the intensity of pain is shown to be very different among different individuals. Different factors such as age, genes, Gender, Age, Type of teeth can influence the pain occurrence in individuals. The most commonly used analgesics being NSAIDs but the response of these analgesics can vary from different individuals based on genetics and plasma life. Recent evidence has shown the use of different analgesics such as corticosteroids for post reduction of endodontic pain by reduction of prostaglandin synthesis. Though different factors are there to influence post endodontic pain and how to manage them there is still a dilemma on how to adequately manage pain reduction post endodontic treatment by different analgesics. In regard to this the present review comprehensively discusses all the analgesics which has been used in endodontics and newer analgesics which can show potential to be used in endodontics for post endodontic pain reduction.
2.Introduction
3.Conclusion
4.References
Keywords
Pain; NSAID; Corticosteroid; Endodontics.
Introduction
Pain is said to be defined as an unpleasant sensory or emotional
experience associated with actual or potential tissue damage [1].
Pain can range widely in intensity, quality, and duration and has
diverse pathophysiologic mechanisms. Although tissue injury is
a common antecedent to pain, pain can be present even when
tissue damage is not present [2, 3]. Pain perception is identified
as a mental process, a psychical adjunct, added to a nociceptive
mechanism [4]. Pain perception is also can be considered as part
of our protective response to prevent further tissue damage [5-7].
The experience of pain is a personal and subjective experience
which can vary from different individuals. Accurate diagnosis and
relevant treatment procedures are successful in affecting a cure. In
endodontics, the occurrence of pain is seen to be multifactorial
and is primarily associated with the activation of the receptors in
the primary afferent fibres, which is inclusive of the unmyelinated
C-fibre and myelinated As-fibre[8]. The need to perform endodontic
treatment is likely due to the inflamed and or infected pulpal
tissue which is shown to affect these fibres to a certain extent.
This pretreatment histologic pulp status can have a direct correlation
to a patient’s odontogenic pain symptoms. Patients' pain
perception is shown to be complex and is seen to be varied among
different individuals. Some of the factors are the following [9].
Previously our team had a rich experience in working on various
research projects across multiple disciplines [10-24]. Now the
growing trend in this area motivated us to pursue this project.
Factors having an overall influence in Pain
Genes: The variation of pain perception is seen to be varied
among different individuals due to the presence of pain gene
which is described as a gene with one or more polymorphisms
that affect the perception of pain response and is considered to
be large families of lineage series. This gene is seen to be varied
among different individuals and is one of the factors responsible
for different pain perception in humans [25].
Gender: It is now seen that pain perception is seen to be varied
based on gender and was seen that females had more pain perception
compared to male. This is due to lifestyle habits which can
have a contributing effect in pain perception with males shown
to sustain painful experiences more frequently than females [26].
Age: Increase of pain threshold is seen to be directly proportional
with the age of the individual with A-delta and C-fibres
seen to comparatively less with increase in age and hence lesser
pain stimulation through the electrical conduction is seen to be
same [27].
Psychological factors: The influence of pain can occur but the
psychological effect of individuals. The factors seen are anxiety
and depression and can have an effect on the individual’s level of
pain perception [28].
Type of Teeth: Another factor to be considered is the type of
teeth, it is seen that molars are shown to have increased incidence
of pain compared to other teeth. This could be due to the various
nerve innervations present which could potentiate pain [29].
Factors influencing the need for endodontic treatment
The primary cause of endodontic pain arises as a result of reactionary
response of the pulp tissue to any causative agents
like dental caries or other irritants. The pulp tissue is shown to
respond to various external stimuli like dental caries, trauma or
even conventional restorative procedures [30]. The progression
of bacteria within the canal plays a pivotal role in pain progression.
Dental caries are shown to have various microbial and other
components which have the capacity to interact with pulp tissue
and produce a response [31]. Pain after endodontic treatment is
seen to be multifactorial which can be a single cause or multiple
causes can associated with pain such as pain with chronic lesion,
non-vital tooth, previously opened canal, extension of either the
filling material or instrument beyond the apex of the tooth and
any leakage in temporary or permanent filling done after endodontic
treatment [32].
Quantitative evaluation of pain
The quantitative evaluation of pain is carried out by using special
measurement scales to assess the intensity of the pain. The widely
used Visual Analogue Scale (VAS) displays a continuous line with
numbers from 1 to 100 placed along the line which represent the
intensity of pain [33-35]. The intensity of pain can be measured
more accurately when more than one scale is used. It is seen that
when evaluating on the Visual Analogue Scale, the intensity of
post-endodontic pain ranges from 5 to 44 points, lasts less than 72
hours and responds well to non-steroidal anti-inflammatory drugs
and acetaminophen [36].
Both NRS and VAS scales are shown to be highly correlated and
the most frequently used pain scales for measurement of pain.
However, these simple pain scales show some limitations in assessment
of pain intensity. They are highly subjective and depend
on many more factors than pain, such as mood. This could lead
to an imprecise assessment of effectiveness of therapies in daily
practice or clinical studies. Moreover, these pain experiences differ
for each individual, which influences the frame of reference
for each person. As a result, it is shown that differences in pain
experiences result in different pain tolerances per person. Pain
scores using the VAS and NRS are presumably affected by the patients
predetermined levels of pain since participants themselves
should indicate pain score, it is not possible to blind participants
for the outcome of the VAS or NRS. Therefore, they can (subconsciously)
contribute to the success or failure of a therapy, by
indicating lower pain scores which overestimate the effect of
treatment. From these perspectives, it is difficult to quantify the
degree of pain in a precise manner. Therefore, there is a need
for a valid, reliable, safe, and low-cost method to determine and
quantify patients’ pain more objectively [37].
Management of endodontic pain
Management of endodontic pain primarily depends on the accurate
diagnosis of the cause of the pain. There are various methods
by which an accurate diagnosis can be made, they are clinical
examination, peri apical testing, pulp testing, radiographic examination
and most importantly the practitioner must be able to differentiate
odontogenic pain from non-odontogenic pain.
There are different reasons for an individual to experience pain
relief following the administration of an analgesic. This could be
due to the efficacy of the drug which was responsible for the alleviation
of pain. However, the temporal relationship between the
administration of the drug and the dissipation of pain may give
patients reason to believe the drug was effective when, in fact,
the pain would have abated without any analgesics to begin with.
Another reason for pain relief is the placebo effect whereby no
pharmacological effect exists. It is purely a psychological effect
that accounts for the alleviation of pain. For example, patients
often assume that more expensive drugs and prescribed drugs inherently
have greater efficacy.
Non-Pharmacological treatment strategies
These strategies include primary dental treatment procedures to
relieve pain like pulpectomy and pulpotomy.
Pulpotomy: The pulpotomy is a treatment method done to remove
the coronal pulp tissue in the chamber without penetrating
pulpal tissue in the root canal systems. It is often performed in
cases of acute pain of pulpal origin when there is insufficient time
to do a complete pulpectomy. The procedure should be done under
adequate isolation with rubber dam being the recommended
mode to prevent further microbiological contamination. After
access is achieved, slow speed round diamond burs is used to remove
pulp tissue to the level of the canal orifice. Slow speed burs
are used to prevent obliteration of the natural funnel at the mouth
of a canal that makes initial penetration easier. High speed burs
can easily destroy that anatomy. Bleeding is typically managed by
a cotton pellet placed firmly against the coronal orifices. The pulpotomy,
including sealing of sedative and antibacterial dressings
in the pulp chamber has been advocated in emergency situations
for many years.
Clinicians frequently note the dramatic effect of opening a chamber
and observing the rapid relief that often follows. It seems reasonable
to assume that these factors constitute the biological basis for its highly predictable effect of reducing pain in patients with
irreversible pulpitis. Furthermore, by avoiding the canal system,
the clinician avoids performing a partial pulpectomy which might
traumatize already inflamed tissue. Partial pulpectomy may result
in profuse haemorrhage due to the rupture of wide diameter vessels
in the central part of the pulp. Less haemorrhage often results
when the extirpation of the pulp is made to the apex of the tooth.
Pulpectomy: Pulpectomy is the course of treatment often used
in patients who present with symptoms of irreversible pulpitis,
or pulp necrosis with or without swelling. Since it is impossible
for the clinician to precisely determine the apical extent of pulpal
pathosis, a pulpectomy offers the advantage of complete removal
of the pulp. Following the pulpectomy it is best to close dressing
must be given in order to prevent contamination from the oral
cavity. Teeth left open to the environment are often involved in
exacerbations during treatment. If there is a flow of exudate from
the canal following instrumentation and irrigation, it is best to
wait to close the tooth until the flow stops. Infrequently, the flow
will continue and, in those instances, a cotton pellet or porous material
can be used as a barrier until the patient returns, preferably
the next day. The goal is to close the tooth as soon as possible in
order to prevent further bacterial penetration.
Pharmacological strategies
Analgesics prescribed during root canal treatment: The analgesics
prescribed for root canal treatment can be broadly classified
into 2 groups based on the mode of action; Centrally acting
drugs act primarily on the central nervous system and are
sometimes considered as compound analgesics which is used in
combination with nonsteroidal anti-inflammatory drugs. They are
classified into 3 categories; sustained-release opioids, immediaterelease
opioids and long-acting opioids [38].
The use of these analgesics is based on the intensity of pain.
Though the use of opioid analgesics is limited in endodontics it
is used to some extent due to their centrally acting effect showing
adverse effects as well as inhibited localized analgesic effect
in localized sites. Some of the opioid’s analgesics prescribed
are morphine, transdermal fentanyl, oxycodone, oxymorphone,
methadone, levorphanol, tramadol and meperidine. Currently,
nonsteroidal anti-inflammatory drugs (NSAIDs) are the drug of
choice for pain reduction in endodontics. These drugs exhibit less
adverse effects but have shown adverse effects such as gastrointestinal
disorders, hypertension or kidney disease when used for
continuous periods of time for a long run. The most common
NSAID option prescribed is ibuprofen 400-600 mg. The second
most commonly used drug is acetaminophen (paracetamol) due
to its lack of inflammatory activity this drug has shown to be ineffective
and has shown some significant side effects on constant
usage for instance nausea, dizziness, drowsiness.
Prostaglandins are the main substances that result in the clinical
manifestation of inflammation. Erythema and heat are caused by
vasodilation in response to prostaglandin E2 (PGE2) primarily
and PGI2 to a lesser degree [39]. In the later stages of inflammation,
prostaglandins maintain the inflammatory response through
chemotaxis of polymorphonuclear cells. Leukocytes at the site of
inflammation are responsible for production and activation of a
variety of cytokines and inflammatory mediators, most notably
interleukins, tumor necrosis factor, histamine, bradykinin, and
prostaglandins. In instance to this NSAID’s play a crucial role for
pain reduction post endodontic treatment.
Nonsteroidal Anti-inflammatory drugs (NSAIDs): They are
FDA approved drugs showing antipyretic, anti-inflammatory and
analgesic properties. They are commonly used drugs for the treatment
of acute pain such as muscle pain, dysmenorrhea, pyrexia,
gout, migraines and for acute trauma case scenarios. NSAIDs can
be classified in three ways. First, NSAIDs can be broadly classified
into two groups based on their chemical structure. Carboxylic acids
make up most NSAIDs together with a few enolic acids, most
notably phenylbutazone [40-42].
Mechanism of action: Arachidonic acid is metabolized to PGG2
and further to PGH2 by prostaglandin G/H synthase, which has
cyclooxygenase and peroxidase activity. Cyclooxygenase catalyses
the production of PGG2, whereas peroxidase catalyses the production
of PGH2. The NSAIDs exert their actions through specifically
inhibiting the enzyme cyclooxygenase without affecting
peroxidase [43, 44].
In doing so, they suppress the clinical signs of redness, swelling,
heat, and ultimately pain. Prostaglandins already present as a result
of either physiologic production or pre-existing inflammation
are not affected by NSAIDs, and a favourable response to the administration
of NSAIDs is not seen until these prostaglandins are
no longer active. Certain agents may also possess properties unrelated
to cyclooxygenase inhibition that aid their anti-inflammatory
effects. These properties include inhibition of superoxide generation
by neutrophils, inhibition of phospholipase C, inhibition of
neutrophil aggregation, and alteration of B and T cells [45].
Cyclooxygenase exists in two isoforms designated COX-1 and
COX-2. Despite their structural similarities, they are encoded by
different genes and are distinct in their distribution and expression
in various tissues. COX-2 expression is induced in response
to bacterial lipopolysaccharide and cytokines, which have an active
role in inflammation. Many of the commonly used NSAIDs have
been shown to more effectively inhibit COX-1, thereby affecting
physiologic cell functions to a greater degree than inflammatory
functions. Considering the functions of the COX isoforms, the
ideal therapeutic NSAIDs should inhibit the inducible COX-2
without affecting the homeostatic COX-1 [46].
Effect of NSAIDs
A. Analgesic Effect
The main mechanism of action of NSAIDs is known to be inhibition
of the cyclooxygenase pathway. COX-l is the ubiquitous
form produced in normal, quiescent conditions and it is a constitutive
protein of normal cells. It is important in the production
of prostaglandins that regulate cellular homeostasis, such as
renal blood flow, and in circumstances where prostaglandins have
a protective function, such as gastric mucus production. COX-
2 is the inducible form of the enzyme, expressed in endothelial
cells, macrophages, synovial fibroblasts, mast cells, chondrocytes
and osteoblasts after tissue trauma, and therefore plays an important
role in inflammation. Inhibition of COX-2 represents the
most likely mechanism of action for NSAID-mediated analgesia and there is currently great interest in the possibility that selective
COX-2 inhibitors might produce analgesia with fewer adverse effects.
Another mechanism of action is inhibition of the lipoxygenase
pathway by inhibiting LTB4 and 12-HETE have been consistently
detected in inflammation [47].
B. Anti-inflammatory Effect
Cyclooxygenase is one of the major factors to cause inflammation
in an individual. NSAIDs are shown to have anti-inflammatory
action by inhibiting the cyclooxygenase pathway in reduction of
inflammation. Another factor of reduction of inflammation is reduction
of lipoxygenase pathway in which arachnoid acid is seen
to be the main factor to cause inflammation. NSAIDs are shown
to inhibit the lipoxygenase pathway as well and are shown to be a
potent anti-inflammatory age [48].
C. Antipyresis Effect
In an event of fever due to various causes such as infection various
cytokines are released such as Interleukins, Tumour Necrosis
Factor-a, interferons which are shown to increase the prostaglandin
production and in turn raising the person's temperature at a
point. On administration of NSAIDs these drugs tend to block
these productions and in turn reduce the individual’s fever.
NSAIDs are widely used for the management of inflammatoryinduced
pain; however, there is a discrepancy between the extent
to which NSAIDs are more useful in control of post-op. Postoperative
pain appears to be more decreased with use of indomethacin
and Rofecoxib at 24 hrs. Although both indomethacin
and Rofecoxib had a similar mechanism of action, small differences
in their chemical structure could influence their efficacy
and pharmacological properties. However, due to the low number
of comparative trials, there is little scientific reason to prefer one
NSAID over the other.
D. COX- 2 selective inhibitors
Celecoxib and rofecoxib are the first generation of selective
COX-2 inhibitors approved by the Food and Drug Administration
(FDA) for pain indications whereas valdecoxib belongs to the
second generation of selective COX-2 inhibitors more recently
approved by the FDA.
A number of studies have examined the analgesic efficacy of coxibs
using the oral surgery model of acute inflammation. However,
there are no published reports examining the efficacy of COX-2
inhibitors in orofacial pain of other etiologies such as endodontic
pain, pain resulting from orthodontic treatment, and pain following
periodontal surgery. Limitations of orally administered selective
COX-2 inhibitors, as well as the non-selective NSAIDs for
dental pain, include delayed onset when compared to an injectable
opioid and the inability to consistently relieve severe pain. The
analgesic dose of rofecoxib, 50mg as a single dose over 24 h, is
greater than the recommended dose for rheumatoid and osteoarthritis
(12.5–25mg), due to concern about a greater incidence of
side-effects with repeated doses, such as extremity edema. The
best strategy for minimizing pain onset is administration of an
NSAID or coxib prior to the postoperative induction of COX-2.
Preemptive analgesia is based on the principle that pain relief
can occur prior to onset of pain in treatment done individuals.
This strategy reduces pain during the immediate postoperative
period as well as at later time points. As a result, fewer analgesics
are consumed, resulting in fewer adverse drug reactions and
enhanced recovery. As the most severe postoperative pain often
occurs within the first 24 h following endodontic therapy, it can
safely be assumed that administration of an NSAID prior to
postoperative pain onset is an effective strategy in pain management.
Multimodal analgesia is another way of achieving effective
postoperative pain control. The combined use of NSAIDs with
an opioid is effective in relieving moderate to severe postoperative
pain as compared to single-drug regimens. Premedication
with celecoxib 200mg and acetaminophen 2000mg was highly effective
in reducing postoperative pain as compared to celecoxib
200mg or acetaminophen 2000mg alone. An effective approach
in managing moderate to severe postoperative endodontic pain is
to prescribe an alternating schedule of an NSAID with an acetaminophen–
opioid combination. An advantage of using a multimodal
approach is that the combination of these three drugs can
have additive analgesic effects.
Adverse effects
Gastrointestinal effects: The primary endpoints were ulcer,
perforation, gastric-outlet obstruction, and upper gastrointestinal
bleeding. The published data from only the first 6months demonstrated
that the incidence of GI effects in the celecoxib group
(0.8%) was numerically lower than the NSAID group (1.5%) [49].
Cardiovascular effects: The current clinical data on the cardiovascular
effects of coxibs is limited. Thromboxane A2 (TxA2)
and prostacyclin I2 (PGI2), products of the cyclooxygenase
pathway, are involved in platelet–vascular homeostasis. PGI2, a
vasodilator, inhibits platelet aggregation and leukocyte adherence,
whereas TxA2, a vasoconstrictor, promotes platelet aggregation.
Selective COX-2 inhibitors suppress the synthesis of PGI2 and
have no effect on TxA2, shifting the hemostatic balance towards
a prothrombotic state with greater potential to initiate adverse occlusive
vascular events .[50]
Renal effects: Inhibition of COX-2 can potentially cause hypertension
and renal failure. Marketing data for celecoxib and
rofecoxib reveals that the incidence of hypertension and edema
does not differ from that of the non-selective NSAIDs [51].
While it is clear that COX-2 inhibitors offer some advantages over
the non-selective NSAIDs in terms of a lower risk of GI toxicity
with long-term use, the effects following short-term use are still
unclear. Until more data are available, COX-2 inhibitors should be
avoided or used with the same caution as conventional NSAIDs
in patients with compromised renal and cardiac function [52].
Corticosteroids: Corticosteroids consist of 2 main categories;
glucocorticoids and mineralocorticoids, cortisol is the primary
glucocorticoid that is continuously synthesized and secreted from
the adrenal cortex. Cortisol and synthetic glucocorticoids circulate
in the blood with 90% or more reversibly bound to plasma
proteins [53]. The adrenal cortex produces approximately 10mg/
day of cortisol in the non-stressed adult. Under severe stress, this
level may be increased more than 10-fold. Glucocorticoids inhibit the production by multiple cells or factors that are important in
producing the inflammatory response. This inhibition is a result
of the effect of glucocorticoids on gene transcription that produces
a decrease in the release of vasoactive and chemo attractive
factors, decreased secretion of lipolytic and proteolytic enzymes,
decreased extravasation of leukocytes to areas of tissue injury,
and ultimately decreased fibrosis. Glucocorticoids have also been
shown to produce a protein vasocortin, which has the ability to
suppress edema that is not suppressed by NSAIDs. The different
glucocorticoids used for reduction of endodontic pain are:
1) Cortisol
2) Cortisone
3) Prednisone
4) Prednisolone
5) 6a-Methylprednisolone
6) Fludrocortisone
7) Triamcinolone
8) Betamethasone
9) Dexamethasone
Corticosteroids have shown varied effect in reduction of pain by
acting on the Polymorphic neutrophils (Marshall, 2002) and inhibiting
the action of prostaglandin synthesis which is the main
causative factor for inflammation and reducing vascular permeability
leading to tissue edema (Vyvey, 2010) [54].
Pharmacology of corticosteroids: The adrenal cortex synthesises
fat-soluble corticosteroids from cholesterol. These steroids
contain 21 carbon atoms in a four membered hydrocarbon ring
system. Corticosteroids comprise glucocorticoids and mineralocorticoids.
In humans, cortisol is the primary glucocorticoid that
is continuously synthesised and secreted from the adrenal cortex
[55]. This process is under the control of the hypothalamus and
anterior pituitary. Along with the adrenal cortex, they make up the
hypothalamic-pituitary-adrenal (HPA) axis, a system that regulates
glucocorticoid level. The hypothalamus produces corticotropinreleasing
hormone (CRH), which travels to the anterior pituitary
via the hypothalamic-hypophyseal portal system and stimulates
the release of adrenocorticotropic hormone (ACTH) by pituitary
corticotrophs [56]. ACTH, a peptide of 39 amino acids, is
the main regulator of cortisol secretion. In turn, glucocorticoids
inhibit ACTH secretion via direct and indirect actions inhibiting
(CRH) neurons resulting in decreased CRH release, and via direct
effects on corticotrophs.
Investigations on the effects of GCS on pain after RCT have used
various routes of administration for the medications, either by
injection (intra-periodontal ligament, supra-periosteal, intraosseous,
parental), systemic ingestion, or as an intracanal medicament.
All investigations except four have used the medication either as a
root canal dressing or as a prescribed medication to be taken after
RCT. The three exceptions used glucocorticoids as a premedication
prior to commencing treatment. The intra-canal use of GCS
may be considered to be safe as only a very small amount of GCS
can be inserted into the root canal and therefore there can only
be very limited, if any, systemic side effects. In addition, placing
the active medicament into the root canal enables it to work directly
on the inflamed tissues around the apex of the tooth root
by diffusing from the canal; in this situation, the root canal acts
as a drug delivery system. On the other hand, oral ingestion, and
particularly injection, of GCS will produce higher doses of the
drug which may provide more anti-inflammatory effects in the
periapical tissues and therefore effectively reduce post-operative
pain, although the systemic side effects may be greater. In addition,
studies that employed systemic GCS used known doses of
the GCS.
Other Analgesic Used
NMDA based analgesics: Flupirtine is a derivative of triaminopyridine
available in the form of maleate salt. It is a non-centrally
acting, non-opioid analgesic with N-methyl-D aspartate (NMDA)
receptor and is shown to be effective in management of postoperative
pain. The analgesic action of flupirtine includes analgesia,
muscle relaxation and neuroprotection properties [57]. Its administration
is done either orally or rectally and undergoes biotransformation
in the liver. Its excretion is seen 72% in the urine and
rest through the faeces. It is well tolerated and has less side effects
[58]. The analgesic action of these drugs is quite different when
compared to NSAIDs. This is by the indirect antagonist action of
potassium channels with the activation of these channels leading
to hyperpolarization of the neuronal membrane and the neuron.
These drugs activate this channel are selective neuronal potassium
channel openers (SNEPCO) and flupirtine being a prototype
drug [59]. The use of flupirtine maleate is used extensively in the
medical field for various applications such as for pain reduction.
It is seen that 100mg of flupirtine maleate has a similar action
when compared to 1gm paracetamol for treatment of acute attack
of migraine[60]. Several studies have shown its analgesic efficacy
with various other analgesics such as diclofenac sodium, piroxicam
and has shown to effectively reduce pain in all this patient.
[61].
Benzodiazepines: Benzodiazepines are among the other drugs
that can be used as adjuvant drugs in times of pain that may enhance
the analgesic effects of NSAIDs for postendodontic pain
reduction. They are shown to have antianxiety effects, anticonvulsant
activity, antidepressant activity and muscle relaxant properties[
62]. Benzodiazepines act as positive modifiers and potent
activators of GABA receptors in the CNS.
GABA receptor agonists showed significant analgesic properties
in the animal pain studies. The GABA receptor agonists are clinically
effective in the treatment of pain, especially when combined
with other analgesics. Benzodiazepines reduces the pain intensity
by reducing the pain-induced anxiety, insomnia and muscle
spasms. The other possible mechanism of action of alprazolam
can be stimulating in the release of endogenous opioids, such as
enkephalins in CNS areas involved in pain processing. Some patients
of the ibuprofen group reported nausea and vomiting more
than the patients of ibuprofen + alprazolam group; this effect
might be due to the anti-nausea effect of benzodiazepines such
as alprazolam [63].
Opioid Analgesics: Opioids produce analgesia by activation of
opioid receptors. Three major families of opioid receptors have
been cloned: the mu, kappa and delta opioid receptors. Three major
families of opioid receptors have been found: the mu, kappa
and delta opioid receptors. The mu opioid receptor is activated
by most clinically used opioids including codeine hydrocodone,
oxycodone, hydrocodone, tramadol and morphine. The kappa
opioid receptor is activated by drugs such as pentazocine and buprenorphine.
No currently approved drugs are selective for the delta receptor. Opioid analgesia occurs by activation of opioid
receptors expressed on neurons in supraspinal sites, spinal sites
and in peripheral tissue [64, 65].
In general, the opioid receptors are thought to inhibit neuronal
activity and their analgesic efficacy is attributed in part to the observation
that opioid receptors are expressed at most of the major
pain processing areas in the central nervous system [66, 67]. Consequently,
systemic administration of opioids produces analgesia
by inhibiting pain transmission at multiple areas of the pain site.
Opioid analgesia occurs by activation of opioid receptors expressed
on neurons in supraspinal sites, spinal sites and in peripheral
tissue. In general, the opioid receptors are thought to inhibit
neuronal activity and their analgesic efficacy is attributed in part to
the observation that opioid receptors are expressed at most of the
major pain processing areas in the central nervous system. Consequently,
systemic administration of opioids produces analgesia
by inhibiting pain transmission at multiple areas in the neuraxis.
Opioids are well recognized to produce variable responses in patients,
with some patients reporting considerably greater analgesia
than others, even after administration of identical doses [68, 69].
In addition, several polymorphisms to the opioid receptors have
been discovered and are associated with altered responses to
opioid analgesics or altered reports of pain intensity. Gender is
another interesting genetic factor associated with altered opioid
responsiveness. Several studies have reported that women demonstrate
significantly greater analgesia to kappa opioids (e.g., pentazocine)
than men. The adverse effect profile of the opioids is
well recognized and includes nausea, emesis and respiratory depression.
Concern has also been raised about opioid abuse and its
impact in the dental setting.
Caffeine: Caffeine has shown recent evidence of pain reduction
in endodontics which is used as adjuvant with acetaminophen. It
is given to patients who are intolerant to NSAIDs and has shown
adequate effect in relieving pain.
Caffeine’s role in pain management is among questionable yet attractive
subjects in this regard. The effects of caffeine on pain
control are somewhat complex yet understanding such effects is
valuable. Before addressing the role of caffeine in pain control,
first we must be familiar with a substance called adenosine. Adenosine
is an inhibitor of neuronal activity in the central nervous
system (CNS) and peripheral nervous system (PNS). There are
four subtypes of adenosine receptors in human bodies including
A1, A2A, A2B, and A3, which are expressed in different parts of
the CNS and PNS [70].
The endogenous compound adenosine has various modulatory
effects in the central and peripheral nervous systems and its receptors
have been known to be involved in antinociception. Enhancing
these receptors could lead to arousal, concentration and
vigilance. The structure of caffeine is similar to adenosine and
therefore Caffeine competes with adenosine for A2a receptors
causing their inhibition. Despite this, caffeine does not alter dopamine
release and therefore does not have abuse potential like
other adenosine blocking agents, such as cocaine. Caffeine could
reduce pain sensation through its effects on adenosine receptors.
Caffeine seems to express its direct effect via central blocking of
adenosine receptors that influence pain signaling or by blocking
of peripheral adenosine receptors on sensory afferents but a clear
mechanism of action is still unknown. Antagonism of adenosine
receptors, as well as inhibition of cyclooxygenase activity at some
sites, may explain caffeine antinociceptive effects and its adjuvant
actions. Interestingly, some researchers claim that genetics can
influence the response of individuals to caffeine consumption.
sOur institution is passionate about high quality evidence based
research and has excelled in various fields [71-81].
Conclusion
The use of different strategies for management of endodontic
pain is known to be used for many ways and is shown to be multifactorial
in nature. The clinician should judiciously assess the
cause of endodontic pain and come to a final decision on which
mode of treatment modality should be considered for pain relief.
The most common analgesics prescribed by clinicians is seen to
be NSAIDs but the recent evidence also suggests other analgesics
showing similar or better analgesic effect with lesser side effects.
The clinician should judiciously consider all recent evidence and
come to an adequate conclusion for the accurate diagnosis and
lesser incidence of endodontic pain.
References
-
[1]. Gathani KM, Raghavendra SS. Scaffolds in regenerative endodontics: A review.
Dent Res J . 2016 Sep;13(5):379.
[2]. Mao JJ, Kim SG, Zhou J, Ye L, Cho S, Suzuki T, et al. Regenerative endodontics: barriers and strategies for clinical translation. Dent Clin North Am. 2012 Jul;56(3):639-49.Pubmed PMID: 22835543.
[3]. Heithersay GS. Calcium hydroxide in the treatment of pulpless teeth with associated pathology. Int. Endod. J. 1975 Jul;8(2):74-93.
[4]. Rafter M. Apexification: a review. Dent Traumatol. 2005 Feb;21(1):1-8.
[5]. Andreasen JO, Farik B, Munksgaard EC. Long-term calcium hydroxide as a root canal dressing may increase risk of root fracture. Dent Traumatol. 2002 Jun;18(3):134-7.
[6]. Iwaya SI, Ikawa M, Kubota M. Revascularization of an immature permanent tooth with apical periodontitis and sinus tract. Dent Traumatol. 2001 Feb;17(4):185-7.
[7]. Lin LM, Ricucci D, Huang GT. Regeneration of the dentine-pulp complex with revitalization/revascularization therapy: challenges and hopes. Int Endod J. 2014 Aug;47(8):713-24.Pubmed PMID: 24330275.
[8]. Nakashima M. Tissue engineering in endodontics. Aust Endod J. 2005 Dec;31(3):111-3.
[9]. NYGAARD-ÖSTBY BI, HJORTDAL O. Tissue formation in the root canal following pulp removal. Eur. J. Oral Sci.1971 Jun;79(3):333-49.
[10]. Murray PE, Garcia-Godoy F, Hargreaves KM. Regenerative endodontics: a review of current status and a call for action. J Endod. 2007 Apr;33(4):377- 90.Pubmed PMID: 17368324.
[11]. Govindaraju L, Gurunathan D. Effectiveness of Chewable Tooth Brush in Children-A Prospective Clinical Study. J Clin Diagn Res. 2017 Mar;11(3):ZC31-ZC34.Pubmed PMID: 28511505.
[12]. Christabel A, Anantanarayanan P, Subash P, Soh CL, Ramanathan M, Muthusekhar MR, et al. Comparison of pterygomaxillary dysjunction with tuberosity separation in isolated Le Fort I osteotomies: a prospective, multi-centre, triple-blind, randomized controlled trial. Int J Oral Maxillofac Surg. 2016 Feb;45(2):180-5.Pubmed PMID: 26338075.
[13]. Soh CL, Narayanan V. Quality of life assessment in patients with dentofacial deformity undergoing orthognathic surgery--a systematic review. Int J Oral Maxillofac Surg. 2013 Aug;42(8):974-80.Pubmed PMID: 23702370.
[14]. Mehta M, Deeksha, Tewari D, Gupta G, Awasthi R, Singh H, et al. Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases. Chem Biol Interact. 2019 Aug 1;308:206- 215.Pubmed PMID: 31136735.
[15]. Ezhilarasan D, Apoorva VS, Ashok Vardhan N. Syzygium cumini extract induced reactive oxygen species-mediated apoptosis in human oral squamous carcinoma cells. J Oral Pathol Med. 2019 Feb;48(2):115-121.Pubmed PMID: 30451321.
[16]. Campeau PM, Kasperaviciute D, Lu JT, Burrage LC, Kim C, Hori M, et al. The genetic basis of DOORS syndrome: an exome-sequencing study. Lancet Neurol. 2014 Jan;13(1):44-58.Pubmed PMID: 24291220.
[17]. Sneha S. Knowledge and awareness regarding antibiotic prophylaxis for infective endocarditis among undergraduate dental students. Asian J Pharm Clin Res. 2016 Oct 1:154-9.
[18]. Christabel SL, Linda Christabel S. Prevalence of type of frenal attachment and morphology of frenum in children, Chennai, Tamil Nadu. World J Dent. 2015 Oct;6(4):203-7.
[19]. Kumar S, Rahman R. Knowledge, awareness, and practices regarding biomedical waste management among undergraduate dental students. Asian J Pharm Clin Res. 2017;10(8):341.
[20]. Sridharan G, Ramani P, Patankar S. Serum metabolomics in oral leukoplakia and oral squamous cell carcinoma. J Cancer Res Ther. 2017 Jul 1;13(3):556- 561.
[21]. Ramesh A, Varghese SS, Doraiswamy JN, Malaiappan S. Herbs as an antioxidant arsenal for periodontal diseases. J Intercult Ethnopharmacol. 2016 Jan 27;5(1):92-6.Pubmed PMID: 27069730.
[22]. Thamaraiselvan M, Elavarasu S, Thangakumaran S, Gadagi JS, Arthie T. Comparative clinical evaluation of coronally advanced flap with or without platelet rich fibrin membrane in the treatment of isolated gingival recession. J Indian Soc Periodontol. 2015 Jan;19(1):66-71.
[23]. Thangaraj SV, Shyamsundar V, Krishnamurthy A, Ramani P, Ganesan K, Muthuswami M, et al. Molecular Portrait of Oral Tongue Squamous Cell Carcinoma Shown by Integrative Meta-Analysis of Expression Profiles with Validations. PLoS One. 2016 Jun 9;11(6):e0156582.Pubmed PMID: 27280700.
[24]. Ponnulakshmi R, Shyamaladevi B, Vijayalakshmi P, Selvaraj J. In silico and in vivo analysis to identify the antidiabetic activity of beta sitosterol in adipose tissue of high fat diet and sucrose induced type-2 diabetic experimental rats. Toxicol Mech Methods. 2019 May;29(4):276-290.Pubmed PMID: 30461321.
[25]. Ramakrishnan M, Shukri M. Fluoride, Fluoridated Toothpaste Efficacy And Its Safety In Children-Review. Int J Pharm Res. 2018 Oct 1;10(04):109-14. [26]. Hacker MC, Mikos AG. Trends in tissue engineering research. Tissue Eng. 2006 Aug 1;12:2049-57.
[27]. Epelman I, Murray PE, Garcia-Godoy F, Kuttler S, Namerow KN. A practitioner survey of opinions toward regenerative endodontics. J Endod. 2009 Sep;35(9):1204-10.Pubmed PMID: 19720217.
[28]. Das A, Nasim I. A knowledge, attitude, and practice survey among endodontic postgraduate students toward regenerative endodontic procedures. Drug invent. today. 2019 May 15;12(5): 893–896.
[29]. Manguno C, Murray PE, Howard C, Madras J, Mangan S, Namerow KN. A survey of dental residents’ expectations for regenerative endodontics. J. Endod. 2012 Feb 1;38(2):137-43.
[30]. Vijayashree Priyadharsini J. In silico validation of the non-antibiotic drugs acetaminophen and ibuprofen as antibacterial agents against red complex pathogens. J Periodontol. 2019 Dec;90(12):1441-1448.Pubmed PMID: 31257588.
[31]. Pc J, Marimuthu T, Devadoss P, Kumar SM. Prevalence and measurement of anterior loop of the mandibular canal using CBCT: A cross sectional study. Clin. Implant Dent. Relat. Res. 2018 Apr 6;20(4):531-4.
[32]. Ramesh A, Varghese S, Jayakumar ND, Malaiappan S. Comparative estimation of sulfiredoxin levels between chronic periodontitis and healthy patients - A case-control study. J Periodontol. 2018 Oct;89(10):1241-1248.Pubmed PMID: 30044495.
[33]. Ramadurai N, Gurunathan D, Samuel AV, Subramanian E, Rodrigues SJ. Effectiveness of 2% Articaine as an anesthetic agent in children: randomized controlled trial. Clin Oral Investig. 2019 Sep;23(9):3543-50.
[34]. Sridharan G, Ramani P, Patankar S, Vijayaraghavan R. Evaluation of salivary metabolomics in oral leukoplakia and oral squamous cell carcinoma. J Oral Pathol Med. 2019 Apr;48(4):299-306.
[35]. Mathew MG, Samuel SR, Soni AJ, Roopa KB. Evaluation of adhesion of Streptococcus mutans, plaque accumulation on zirconia and stainless steel crowns, and surrounding gingival inflammation in primary molars: randomized controlled trial. Clin Oral Investig. 2020 Sep;24(9):1-6.Pubmed PMID: 31955271.
[36]. Samuel SR. Can 5-year-olds sensibly self-report the impact of developmental enamel defects on their quality of life? Int J Paediatr Dent. 2021 Mar;31(2):285-286.Pubmed PMID: 32416620.
[37]. R H, Ramani P, Ramanathan A, R JM, S G, Ramasubramanian A, et al. CYP2 C9 polymorphism among patients with oral squamous cell carcinoma and its role in altering the metabolism of benzo[a]pyrene. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Sep;130(3):306-312.Pubmed PMID: 32773350.
[38]. Chandrasekar R, Chandrasekhar S, Sundari KKS, Ravi P. Development and validation of a formula for objective assessment of cervical vertebral bone age. Prog Orthod. 2020 Oct 12;21(1):38.Pubmed PMID: 33043408.
[39]. Vijayashree Priyadharsini J, Smiline Girija AS, Paramasivam A. In silico analysis of virulence genes in an emerging dental pathogen A. baumannii and related species. Arch Oral Biol. 2018 Oct;94:93-98.Pubmed PMID: 30015217.